LFG
MGX icon

Larson Financial Group’s Metagenomi Therapeutics MGX Stock Holding History

Larson Financial Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50
Closed -$67 – 3941
2026
Q1 		$67 Hold
50
– – ﹤0.01% 3539
2025
Q4 		$81 Hold
50
– – ﹤0.01% 3353
2025
Q3 		$119 Sell
50
-76
-60% -$154 ﹤0.01% 3310
2025
Q2 		$186 Hold
126
– – ﹤0.01% 3072
2025
Q1 		$171 Buy
126
+76
+152% +$181 ﹤0.01% 2824
2024
Q4 		$181 Hold
50
– – ﹤0.01% 2469
2024
Q3 		$109 Hold
50
– – ﹤0.01% 2518
2024
Q2 		$204 Hold
50
– – ﹤0.01% 2064
2024
Q1 		$528 Buy
+50
New +$575 ﹤0.01% 1552

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Larson Financial Group's MGX Position: Q2 2026 in Review

Larson Financial Group sold out of Metagenomi Therapeutics (MGX) in Q2 2026, closing a stake of 50 shares — an estimated $67 sold.

Larson Financial Group first reported a position in MGX in Q1 2024 and held it in 9 quarters. The position peaked at $528 in Q1 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Larson Financial Group reported no remaining Metagenomi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Larson Financial Group sold 50 Metagenomi Therapeutics shares in Q2 2026, an estimated $67.
  • Larson Financial Group first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 9 quarters.
  • Larson Financial Group's Metagenomi Therapeutics position peaked at $528 in Q1 2024.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.